Theranexus SA (FR:ALTHX)
:ALTHX
Want to see FR:ALTHX full AI Analyst Report?
Top Page
Theranexus SA
(ALTHX)
Select Model
Select Model
Rating:47Neutral
Price Target:
€3.50
▲(72.41% Upside)
Action:Reiterated
Date:05/03/26
The score is held down primarily by very weak financial performance (losses, cash burn, and revenue collapsing to zero in 2025) and limited valuation support due to negative earnings. This is partly offset by moderately positive technicals, with the stock trading above key moving averages and neutral momentum indicators.
Positive Factors
Partnership-driven development
Theranexus' model of advancing clinical-stage programs while leveraging partnerships reduces capital intensity and shares development risk. For a small biotech, durable partner relationships can provide expertise, non-dilutive resources or co-development paths that increase the odds of progressing assets over the medium term.
Negative Factors
Persistent unprofitability
Theranexus is loss-making across reported periods with negative gross profit and deeply negative operating results. Chronic unprofitability steadily erodes capitalization, forces recurrent external funding, limits reinvestment capacity, and creates a durable risk to long-term viability absent a clear path to sustained revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnership-driven development
Theranexus' model of advancing clinical-stage programs while leveraging partnerships reduces capital intensity and shares development risk. For a small biotech, durable partner relationships can provide expertise, non-dilutive resources or co-development paths that increase the odds of progressing assets over the medium term.
Read all positive factors
Theranexus SA (ALTHX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€48.58M
Dividend YieldN/A
Average Volume (3M)133.77K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue GrowthN/A
EPS Growth10.30%
CountryFR
Employees12
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.22
Shares Outstanding14,472,778
10 Day Avg. Volume147,352
30 Day Avg. Volume133,766
Financial Highlights & Ratios
PEG Ratio-2.06
Price to Book (P/B)14.83
Price to Sales (P/S)0.00
P/FCF Ratio-31.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.78
Revenue Forecast (FY)N/A
Theranexus SA Business Overview & Revenue Model
Company Description
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders...
How the Company Makes Money
null...
Theranexus SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 2.28M | 296.33K | 414.90K | 602.00 |
| Gross Profit | -108.60K | -333.55K | -4.64M | 82.90K | -8.82M |
| EBITDA | -10.12M | -2.53M | -7.39M | -5.93M | -8.67M |
| Net Income | -3.00M | -1.77M | -6.83M | -6.57M | -8.15M |
Balance Sheet | |||||
| Total Assets | 10.54M | 3.74M | 7.24M | 12.05M | 16.89M |
| Cash, Cash Equivalents and Short-Term Investments | 7.77M | 966.59K | 4.90M | 9.11M | 12.53M |
| Total Debt | 2.88M | 2.87M | 3.64M | 4.89M | 5.33M |
| Total Liabilities | 7.64M | 5.40M | 5.02M | 6.33M | 6.71M |
| Stockholders Equity | 1.99M | -1.66M | 2.22M | 5.73M | 10.18M |
Cash Flow | |||||
| Free Cash Flow | -939.81K | -3.40M | -6.40M | -5.41M | -6.40M |
| Operating Cash Flow | -883.76K | -3.37M | -6.36M | -5.37M | -6.25M |
| Investing Cash Flow | -168.23K | 77.04K | -61.11K | 323.53K | -150.62K |
| Financing Cash Flow | 7.85M | -646.42K | 2.22M | 1.63M | 7.71M |
Theranexus SA Technical Analysis
Positive
2.03
Price Trends
3.26
Positive
2.96
Positive
2.58
Positive
Market Momentum
0.03
Positive
51.42
Neutral
18.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHX, the sentiment is Positive. The current price of 2.03 is below the 20-day moving average (MA) of 3.43, below the 50-day MA of 3.26, and below the 200-day MA of 2.58, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 51.42 is Neutral, neither overbought nor oversold. The STOCH value of 18.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTHX.
Theranexus SA Peers Comparison
UnderperformOutperform
Sector (51)
FR:ALTHX
Theranexus SA
3.40
2.40
239.84%
GB:0NWK
Valerio Therapeutics
0.18
0.12
181.54%
DE:3HB
Hybrigenics SA Class A
0.01
<0.01
30.00%
DE:0N6A
TME Pharma N.V.
0.08
<0.01
1.33%
FR:ALINT
IntegraGen SA
0.21
-0.43
-67.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.